Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vidya Perera

Showing results (21-30 of 41) with videos related to

Pageof 5
Sort By:
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 20, 2018
Further Studies to Support the Use of Coproporphyrin I and III as Novel Clinical Biomarkers for Evaluating the Potential for Organic Anion Transporting Polypeptide 1B1 and OATP1B3 InhibitionHong Shen, Lisa Christopher, Yurong Lai, et al.
Expert Opinion on Drug Metabolism & Toxicology|May 7, 2013
Considering CYP1A2 phenotype and genotype for optimizing the dose of olanzapine in the management of schizophreniaVidya Perera, Annette S Gross, Thomas M Polasek, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|June 26, 2024
Effect of Activated Charcoal on Mavacamten Pharmacokinetics in Healthy ParticipantsSamira Merali, Manting Chiang, Caroline Sychterz, et al.
Scientific Reports|July 18, 2024
Safety, tolerability, pharmacokinetics and pharmacodynamics of milvexian with aspirin and/or clopidogrel in healthy participantsVidya Perera, Grigor Abelian, Joseph Luettgen, et al.
Scientific Reports|March 26, 2022
Safety, pharmacokinetics, and pharmacodynamics of milvexian in healthy Japanese participantsVidya Perera, Zhaoqing Wang, Susan Lubin, et al.
CPT: Pharmacometrics & Systems Pharmacology|March 2, 2023
Evaluation of safety, pharmacokinetics, and pharmacodynamics of apixaban in pediatric subjects at risk of venous or arterial thrombotic disorderSamira J Merali, Wonkyung Byon, Yogesh T Patel, et al.
British Journal of Clinical Pharmacology|December 2, 2017
Prediction of olanzapine exposure in individual patients using physiologically based pharmacokinetic modelling and simulationThomas M Polasek, Geoffrey T Tucker, Michael J Sorich, et al.
British Journal of Clinical Pharmacology|April 30, 2014
Optimal sampling of antipsychotic medicines: a pharmacometric approach for clinical practiceVidya Perera, Robert R Bies, Gary Mo, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|December 25, 2018
Phase I study of single-dose pharmacokinetics and pharmacodynamics of belatacept in adolescent kidney transplant recipientsAsha Moudgil, Vikas R Dharnidharka, Daniel I Feig, et al.
CPT: Pharmacometrics & Systems Pharmacology|May 2, 2024
Recommendation of mavacamten posology by model-based analyses in adults with obstructive hypertrophic cardiomyopathySamira Merali, David H Salinger, Maria Palmisano, et al.
Pageof 5

Showing results (21-30 of 41) with videos related to

Sort By:
Pageof 5
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 20, 2018
Further Studies to Support the Use of Coproporphyrin I and III as Novel Clinical Biomarkers for Evaluating the Potential for Organic Anion Transporting Polypeptide 1B1 and OATP1B3 InhibitionHong Shen, Lisa Christopher, Yurong Lai, et al.
Expert Opinion on Drug Metabolism & Toxicology|May 7, 2013
Considering CYP1A2 phenotype and genotype for optimizing the dose of olanzapine in the management of schizophreniaVidya Perera, Annette S Gross, Thomas M Polasek, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|June 26, 2024
Effect of Activated Charcoal on Mavacamten Pharmacokinetics in Healthy ParticipantsSamira Merali, Manting Chiang, Caroline Sychterz, et al.
Scientific Reports|July 18, 2024
Safety, tolerability, pharmacokinetics and pharmacodynamics of milvexian with aspirin and/or clopidogrel in healthy participantsVidya Perera, Grigor Abelian, Joseph Luettgen, et al.
Scientific Reports|March 26, 2022
Safety, pharmacokinetics, and pharmacodynamics of milvexian in healthy Japanese participantsVidya Perera, Zhaoqing Wang, Susan Lubin, et al.
CPT: Pharmacometrics & Systems Pharmacology|March 2, 2023
Evaluation of safety, pharmacokinetics, and pharmacodynamics of apixaban in pediatric subjects at risk of venous or arterial thrombotic disorderSamira J Merali, Wonkyung Byon, Yogesh T Patel, et al.
British Journal of Clinical Pharmacology|December 2, 2017
Prediction of olanzapine exposure in individual patients using physiologically based pharmacokinetic modelling and simulationThomas M Polasek, Geoffrey T Tucker, Michael J Sorich, et al.
British Journal of Clinical Pharmacology|April 30, 2014
Optimal sampling of antipsychotic medicines: a pharmacometric approach for clinical practiceVidya Perera, Robert R Bies, Gary Mo, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|December 25, 2018
Phase I study of single-dose pharmacokinetics and pharmacodynamics of belatacept in adolescent kidney transplant recipientsAsha Moudgil, Vikas R Dharnidharka, Daniel I Feig, et al.
CPT: Pharmacometrics & Systems Pharmacology|May 2, 2024
Recommendation of mavacamten posology by model-based analyses in adults with obstructive hypertrophic cardiomyopathySamira Merali, David H Salinger, Maria Palmisano, et al.
Pageof 5